tbuckley/cabot-search huggingface dataset:
Permanent stoma use in rectal cancer surgery in Canada: A population-based analysis.
Authors: Geoffrey A. Porter, Tonia Forte, Rami Rahal, Sharon Fung, Jin Niu, Heather E. Bryant
Journal: Journal of Clinical Oncology (2014)

6622 Background: Sphincter preservation is important for many patients with rectal cancer; avoidance of a permanent stoma (either colostomy or ileostomy) is a well-accepted quality indicator of rectal cancer care. This study describes, at a population level, the frequency of permanent stoma (PS) use in rectal cancer surgery in Canada. In addition, this study examines potential disparities in PS use related to income, geography and immigration status. Methods: Patients undergoing resection for primary adenocarcinoma of the rectum in Canada during fiscal years 2007/08-2011/12 with a valid postal code were included; procedure codes from the discharge abstract database were used to categorize surgery as involving either a permanent stoma (PS), temporary stoma (TS) or no stoma (NS). Income for urban Canada was categorized according to neighbourhood income quintile, and immigration density represented the percentage of immigrant/non-permanent populations living in a dissemination area based on census information. Geography was examined according to province of residence, statistical area classification (SAC) of urban/rural, and travel time (in minutes) to nearest hospital Results: Among the 10,559 patients undergoing rectal cancer resection, 3,895 (36.9 %) underwent a PS, 3,501 (33.2 %) a TS, and 3,163 (30.0%) had NS. Significant variation in PS rates was identified among 9 Canadian provinces (range 35.1%- 51.4%; p<0.0001). The table below shows increased rates of PS among patients living in rural/remote areas, low income neighbourhoods, and those with longer travel time to hospital. Lower rates of PS were seen among patients residing in areas of higher immigration density. Conclusions: Significant variation exists in the use of PS for rectal cancer in Canada, particularly related to geography. Better understanding of root causes of such variation will be important to guide targeted initiatives aimed at optimizing the quality of rectal cancer care at a population level. % with PS P value SAC 0.0003 Urban 35.9 Rural 36.1 Rural - remote 40.1 Rural - very remote 41.9 Travel time (minutes) <0.0001 0-39 35.9 40-179 41.9 ≥ 180 42.6 Immigrant density <0.0001 Low 37.9 Middle 35.7 High 30.3 Income 0.003 Lowest quintile 38.5 Highest quintile 35.4
A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM)
Authors: P. M. Voorhees, R. F. Manges, G. Somlo, S. Lentzsch, S. Jagannath, P. Sonneveld, R. C. Frank, S. Zweegman, P. W. Wijermans, S. Thomas
Journal: Journal of Clinical Oncology (2009)

8527 Background: Relapsed/refractory MM constitutes a specific and unmet medical need with poor overall response and survival. Interleukin-6 (IL-6) plays an important role in MM cell proliferation, survival, and corticosteroid resistance and previous studies have shown clinical benefit from anti-IL-6 therapy. We therefore evaluated the combination of CNTO328, a chimeric monoclonal antibody with high affinity for human IL-6, and dexamethasone (dex) in pts with relapsed/refractory MM. Methods: Pts were treated with 6 mg/kg CNTO328 IV Q2 weeks. Oral dex (40mg) was given once daily, days 1–4, 9–12, and 17–20 for a max of 4 cycles; and on days 1–4 for subsequent cycles. Inclusion criteria were &gt; 2 prior lines of systemic therapy, creatinine clearance &gt;20 ml/min, platelets &gt;50,000/mm 3 , and neutrophils &gt;1000/mm 3 . Primary endpoint was overall response with secondary endpoints of time to progression, incidence of AEs and SAEs. Results: Thirty-nine pts received at least 1 infusion of CNTO328 in combination with dex - median age 66 yrs (range 43–89), median disease duration 4.2 yrs (1–13), median lines of prior therapy 5 (2–9) including bortezomib (100%), IMIDs (87%), and ASCT (59%). The median duration of therapy was 3.3 months (0.5–21+). Of the 36 pts who were evaluable, the overall response rate (CR+PR+MR) using EBMT criteria was 31% (7PR, 4MR). An additional 4 uMR and 4 SD lasting ≥3 months have been reported. PRs were durable; 6 out of 7 pts had responses ranging from 3 months to up to more than 1 year (with 1 still ongoing for more than 1 year). Duration of MRs ranged from 2–5 months. Responses were seen in pts relapsing after and refractory to at least one other prior treatment including bortezomib, IMIDs, or steroids. Median time to disease progression (PD) was 3.7 months (0.3–18+). Main reasons for treatment discontinuation were PD (24) and AEs (6). Hematologic toxicities Grade ≥ 3 were common though not dose-limiting. Three pts had Grade ≥ 3 infections considered reasonably related to CNTO328. Conclusions: CNTO 328 in combination with dex shows promising preliminary activity in this heavily pretreated patient population with an acceptable safety profile. Further investigation is ongoing. No significant financial relationships to disclose.
Metabolic syndrome (MetS) after platinum-based chemotherapy (CHEM): A multicenter study of North American testicular cancer survivors (TCS).
Authors: Mohammad Issam Abu Zaid, Wambui G. Gathirua-Mwangi, AnnaLynn Williams, Chunkit Fung, Patrick O. Monahan, Darren R. Feldman, Robert James Hamilton, David J. Vaughn, Clair Beard, Ryan Cook, Sandra K. Althouse, Omar El Charif, Howard D. Sesso, Shirin Ardeshirrouhanifard, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis
Journal: Journal of Clinical Oncology (2017)

102 Background: Testicular cancer has an excellent prognosis since the introduction of platinum-based CHEM. However, several European studies report an excess of cardiovascular disease (CVD) in TCS. MetS is a cluster of cardiovascular risk factors that doubles CVD risk, with several European series noting a prevalence ranging from 13-39% in TCS. In the first large multi-center North American study of TCS, we examine the prevalence of and potential risk factors for MetS after modern CHEM (NCI R01 CA157823). Methods: Eligible TCS were &lt;50 y at diagnosis and treated with only first line CHEM after 1990. TCS underwent physical exams, completed questionnaires regarding co-morbidities and health behaviors and had lipid panels, testosterone, and serum soluble cell adhesion molecule-1 (sICAM-1) measured. A single nucleotide polymorphism, rs523349 (V89L), in 5-α-reductase gene ( SRD5A2) previously suggested to associate with MetS in TCS was genotyped. MetS was defined as ≥3 of the following: hypertension (HTN), waist circumference ≥102 cm, triglycerides ≥150 mg/dL, HDL ≤40 mg/dL, and diabetes (Alberti et al, Circulation 2009). Controls (1:1) derived from the National Health and Nutrition Examination Survey were matched on age, race, and educational status. Results: We evaluated 486 consecutively enrolled TCS. Median age at evaluation was 38 y (range: 19-68). TCS had higher prevalence of HTN compared to controls (43% vs 31%, P &lt; .01) but lower prevalence of low HDL (24% vs 35%, P &lt; .01) and abdominal obesity (28% vs 40%, P &lt; .01). Prevalence of MetS was comparable (21% TCS; 22% controls, P = .59). In multivariate analysis, age at evaluation (P &lt; .01), serum testosterone &lt;3.0 ng/mL (OR = 2.0, P = .005), and elevated sICAM-1 (OR for quartiles 2, 3, 4 vs lowest quartile: 2.7 (P = .01), 3.1 (P &lt; .01), and 3.6 (P &lt; .01), respectively) significantly correlated with MetS. The variant rs523349 (VL/LL) did not associate with MetS. Conclusions: One in 5 TCS treated with CHEM developed MetS. Providers should screen for MetS, adequately treat hypogonadism, HTN and hyperlipidemia, and encourage TCS to maintain a healthy lifestyle. Significant elevations in sICAM-1 underscore a role for inflammation in MetS.
Quantitating pathologic response to neoadjuvant chemotherapy in <i>KRAS</i>-mutated versus nonmutated lung cancers.
Authors: Jamie E. Chaft, Paul K. Paik, Camelia S. Sima, Mark G. Kris, Lee M. Krug, Christopher G. Azzoli, Gregory J. Riely, Maria Catherine Pietanza, Valerie W. Rusch, William D Travis, Naiyer A. Rizvi
Journal: Journal of Clinical Oncology (2012)

7014 Background: Trials of neoadjuvant chemotherapy in non-small cell lung cancers (NSCLC) have demonstrated that pathologic response correlates with downstaging and survival. There is controversy as to whether KRAS mutated patients (pts) have the same benefit with adjuvant chemotherapy as non-mutated pts however the impact of KRAS mutations on response to neoadjuvant therapy has not been reported. Methods: Pts with resectable stage I-III non-squamous NSCLCs were treated with 4 cycles of cisplatin, docetaxel, and bevacizumab, followed by surgical resection. Tumors were tested for KRAS mutations. Percent treatment effect (necrosis, inflammation, fibrosis) was quantified histologically. Pts were followed until disease recurrence and/or death. Binary variables were compared using the Fisher’s Exact Test. Survival was assessed by pathological response based on the literature (≥90 vs &lt;90%) using the Kaplan-Meier method, stratified by stage (IB-IIB vs. III) and by KRAS mutation. Results: We accrued 51 pts. 34/51 (67%) had clinical stage IIIA disease. 48 had molecular testing: 14/48 (29%) had KRAS mutations and 4/48 (8%) had EGFR mutations. The median follow-up was 2 years (yr) (range, 3-63 months). 41 pts had resection and analysis for pathological response. The 2 yr disease free survival (DFS) and overall survival (OS) were superior in the 11/41 (27%) with ≥90% versus those with &lt;90% treatment effect: DFS 91% vs. 56%, p=0.029 and OS 100% vs. 60%, p=0.013. These outcomes remained significant when adjusted for stage. For pts with KRAS mutations, 0 of 10 tumors analyzed had ≥90% treatment effect whereas 11 of 31 (35%) pts with wild-type KRAS had ≥90%, p=0.039. There was an inferior median OS for KRAS mutated pts (22 months) compared to pts without a known KRAS mutation, (Not Reached, p=0.03). Conclusions: Following neoadjuvant chemotherapy, pts with tumors having ≥90% necrosis had improved survival. There were no patients with KRAS mutation that achieved ≥90% treatment effect in response to cisplatin, docetaxel, and bevacizumab. Adaptive adjuvant trial strategies to improve upon outcomes of those with &lt;90% necrosis at resection and new approaches specifically targeting KRAS-mutated NSCLCs are needed.
HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).
Authors: Kathy Miller, Javier Cortes, Sara A. Hurvitz, Ian E. Krop, Debu Tripathy, Sunil Verma, Michelle Dionne, Karen Campbell, Joseph G. Reynolds, Thomas J. Wickham, Istvan Molnar, Denise A. Yardley
Journal: Journal of Clinical Oncology (2016)

TPS631 Background: Although HER2-targeted therapies such as pertuzumab and T-DM1 have improved patient outcomes, treatment resistance typically occurs. MM-302 is a HER2-targeted liposomal doxorubicin in development by Merrimack Pharmaceuticals. In a Phase 1 study, patients with HER2-positive metastatic breast cancer (MBC) were treated with MM-302 alone and in combination with trastuzumab with or without cyclophosphamide. MM-302 had an acceptable safety profile, and promising efficacy was observed in patients not previously exposed to an anthracycline. Trial design/Methods: HERMIONE (NCT02213744) is a randomized Phase 2, two-arm, open-label trial designed to evaluate if MM-302 can address an unmet medical need in patients with anthracycline naïve, trastuzumab-, pertuzumab- and T-DM1-pretreated HER2-positive locally advanced breast cancer (LABC)/MBC. Patients are randomized 1:1 to receive MM-302 (30mg/m2, Q3W) plus trastuzumab (6mg/kg, Q3W) or chemotherapy of physician’s choice (vinorelbine, capecitabine, or gemcitabine) plus trastuzumab (6mg/kg, Q3W). Eligibility criteria: Centrally confirmed HER2-positive LABC/MBC, no prior anthracycline exposure, prior trastuzumab in any setting, prior T-DM1 in the LABC/MBC setting, prior pertuzumab in LABC/MBC setting or disease recurrence within 12 months of neoadjuvant/adjuvant treatment, unlimited prior lines of therapy, ECOG 0-1 and LVEF ≥ 50%. CNS metastases are permitted if stable and without symptoms or steroids for 4 weeks. Specific aims: The primary endpoint is progression free survival (PFS) as assessed by an independent blinded review of tumor assessments. Secondary endpoints include investigator assessed PFS, overall survival, response rate, safety and patient related outcomes. Statistics: 250 patients will be enrolled to observe 191 PFS events for 90% power to detect a Hazard Ratio of 0.625. The MM-302 arm will be compared to the control arm on the primary endpoint of PFS using a stratified log-rank test at one-sided 0.025 level. Clinical trial information: NCT02213744.
Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.
Authors: Oleg Gluz, Hans Heinrich Kreipe, Matthias Christgen, Tom Degenhardt, Ronald E. Kates, Cornelia Liedtke, Steven Shak, Michael R. Clemens, Marwa Salem, Susanne Markmann, Bernd Liedtke, Bahriye Aktas, Stephan Henschen, Anke Pollmanns, Petra Krabisch, Christoph Uleer, Doris Augustin, Christoph Thomssen, Ulrike Nitz, Nadia Harbeck
Journal: Journal of Clinical Oncology (2012)

552 Background: Use of multi-gene real-time PCR (RT-PCR) based assays e.g. Recurrence Score (RS) and single markers (grade, uPA/PAI-1, ER/PR, HER2, KI-67) is currently controversially discussed in early BC. Here, we present the final WSG-planB trial correlation analysis of risk assessment tools and first prospective comparison of independent central pathology IHC/FISH assessment and RT-PCR for single markers. Methods: Plan B trial (n=2,448 randomized for 6xTC vs. 4xEC-4xDOC in locally HER2- BC). RS has been used as selection criterion for cht omission in HR+ BC (if RS&lt;11 in pN0 or pN1). uPA/PAI-1 was optionally obtained. Grade, ER/PR, HER2 (IHC/FISH), Ki-67 were evaluated by the independent trial pathologist in all tumors. Results: From 04/09 to 11/11, 3196 patients have been recruited and 2448 randomized. RS distribution in 2551 HR+ tumors: 0-11 (18%), 12-25 (60%), &gt;25 (22%). In 354 pN0-1 patients, cht was omitted based on low risk RS (88% compliance). Central grade for n=3038 and IHC/FISH results are currently available in n=1476. Moderately significant correlations were only found between RS and both central grade (rs=0.313; p&lt;0.001) as well as Ki-67 (rs=0.374; p&lt;0.001) and a weak one for uPA/PAI-1, particularly due to poor correlations within the RS group &lt;26. In 1476 locally HER2- cases, n=9 were found as 3+ and/or FISH+ by central analysis. In 6 HR+/HER2+ cases, RS revealed 2 positive, 2 equivocal and 2 negative results. In 7 cases positive for HER2 by RT-PCR central pathology revealed 4 negative results. 24 locally HR+ cases are assessed as HR- in central pathology (2%). Among these, 6 were ER positive by RT-PCR. Final correlation analyses will be presented at the meeting. Conclusions: These first prospective data demonstrate that high-risk status according to RS is predictive of high risk by other factors, but the converse is not true. Regarding controversial HER2 and HR status by RT-PCR and IHC/FISH, we found few cases with false-negative or positive RT-PCR results in HER2- BC by local pathology. However, these discrepancies could potentially have a substantial impact on clinical patient management.
A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
Authors: Antonio Palumbo, Sara Bringhen, Davide Rossi, Valeria Magarotto, Francesco Di Raimondo, Roberto Ria, Massimo Offidani, Chiara Nozzoli, Francesca Patriarca, Vincenzo Callea, Giulia Benevolo, Roberto Marasca, Tommasina Guglielmelli, Manuela Rizzo, Mariella Grasso, Maria Teresa Petrucci, Paola Omedè, Gianluca Gaidano, Mario Boccadoro
Journal: Blood (2008)
DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).
Authors: Matt D. Galsky, Andrew V. Uzilov, Russell Bailey McBride, Huan Wang, Vaibhav G. Patel, John Sfakianos, Li Wang, Nicholas Akers, Gopa Iyer, David B. Solit, Takuro Saito, Mireia Castillo-Martin, Noah M. Hahn, Sumanta K. Pal, Mark T. Fleming, Ralph J. Hauke, Bojan Losic, Sacha Gnjatic, Rong Chen, Nina Bhardwaj
Journal: Journal of Clinical Oncology (2017)

300 Background: Somatic mut in DDR genes have been associated with increased sensitivity to cisplatin in UC. Higher mut load has correlated with response to immune checkpoint blockade. We hypothesized that DDR mut result in higher mut load and DDR mut UC may be particularly sensitive to both chemotherapy and immune checkpoint blockade. Methods: Three cohorts were utilized: (1) TCGA UC cohort (n = 389), (2) Mount Sinai (MS) cohort (n = 67) of UC (cystectomy) specimens subjected to targeted exome sequencing for 341 genes (MSK-IMPACT), and (3) Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab (GCI) in metastatic UC from which 28/36 enrolled patients (pts) had specimens suitable for whole exome sequencing. DDR mut were defined as somatic alterations in one of 52 genes. Deleterious (del) mut were defined as nonsense, frameshift, splice site, or hotspot point mut. Results: The mut load using all genes in the TCGA cohort, and restricted to the 341 IMPACT genes, were highly correlated (r s = 0.81, p &lt; 0.001). Associations between del DDR mut and mut load are shown (Table). In the MS cohort, CD8+cells/mm2 by IHC were higher in tumors with del DDR mut versus no DDR mut (p = 0.04). In the GCI cohort, the sensitivity, specificity, positive predictive value, and negative predictive value of a del DDR mut for objective response to treatment was 40.9% (95% CI 20.7-63.7%), 86.7% (95% CI 42.1-99.4%), 90% (55.5-99.8%), and 31.6% (95% CI 12.6-56.6%), respectively. Median progression-free survival in the GCI cohort was 308 days (95% CI 270-NR) in del DDR mut and 196 days (95% CI 185-372) in others (p = 0.24). Notably, 2/9 pts with del DDR mutations, and with the highest mut loads, achieved complete responses after GCI and are alive without evidence of disease at 2.1+ and 1.8+ years. Conclusions: DDR mut are associated with higher mut load in UC, a high likelihood of response to GCI, and may identify a subset of pts achieving durable disease control. GC plus PD-1/PD-L1 blockade should be explored in DDR mut UC. Clinical trial information: NCT01524991. [Table: see text]
Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).
Authors: David Shao Peng Tan, Christian K. Kollmannsberger, Sebastien J. Hotte, David W. Cescon, Ivan Diaz-Padilla, David W. Hedley, Daniel John Renouf, Albiruni R.A. Razak, Karen A. Gelmon, Hal W. Hirte, Lisa Wang, Monika Wizemann, Jeffrey Moscow, Helen X. Chen, Lillian L. Siu, Philippe L. Bedard
Journal: Journal of Clinical Oncology (2013)

2534 Background: Preclinical data suggest that combined Ang1/2 and mTOR blockade has synergistic anti-cancer activity. The combination of Tr (inhibits angiogenesis by preventing interaction of Ang1/2 with Tie2) with the mTOR inhibitor T was evaluated in pts with advanced solid tumors to determine safety, tolerability, maximum tolerated dose (MTD), pharmacodynamics and preliminary antitumor activity. Methods: Pts were enrolled using 3+3 design. Tr and T were dosed on Day 1 (D1), 8, 15 and 22 of a 28-day cycle. Peripheral blood was collected for evaluation of Tie2-expressing monocytes (TEMs) and thymidine phosphorylase (TP) (an angiogenic enzyme increased in TEMs upon Tie2 stimulation) by flow cytometry. Tumor response was assessed every 2 cycles. Results: 13 pts have been enrolled, 6 at dose level (DL) 1 (15mg/kg Tr + 25mg T) and 7 (1 died from disease before DLT assessment) at DL -1 (15mg/kg Tr + 20mg T). Median age was 57yrs, ECOG 0-1, median previous chemotherapy lines 3 (range 1-8). In DL 1, 1/6 pts experienced DLT (Grade (Gr) 2 pneumonitis). In view of frequent Gr2 adverse events (AEs) in DL 1, DL -1 was evaluated with DLTs in 2/6 evaluable pts (Gr3 mucositis and intolerable Gr2 limb edema preventing start of cycle 2 within 14 days). The most common related AEs (all Gr across both DL) were: fatigue (77%), edema (69%), anorexia (62%), and nausea (54%). Common Gr≥3 AEs included lymphopenia (23%) and fatigue (23%). Of 10 evaluable pts, best RECIST responses were: 1 breast cancer pt (ER+/ HER2-/ PIK3CA mutant) with PR (now in cycle 9), 7 pts with SD, and 2 pts with PD. Four pts with ovarian cancer (1 PIK3CAmutant) had SD ≥11weeks with 2/3 pts (1 not evaluable) demonstrating GCIG response (&gt;50% decrease in CA125). In preliminary analyses, TP expression in TEMs was decreased (mean -18%) in 4pts with tumor shrinkage, but increased (+6%) in 1pt with tumor growth, suggesting a trend between reduced TP and tumor response. Conclusions: The MTD was exceeded at 15mg/kg Tr and 20mg T weekly. The safety of 10mg/kg Tr and 20mg T weekly is currently being evaluated. The combination of Tr and T shows early signs of antitumor activity. TP expression in TEMs by flow cytometry as an early marker of treatment benefit warrants further evaluation. Clinical trial information: NCT01548482.
A phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors.
Authors: Nicolas Isambert, Antoine Hollebecque, Yann Berge, Hein van Ingen, Silvano Brienza, Alice Destaillats, Jean-Charles Soria, Pierre Fumoleau, Jean-Pierre Delord
Journal: Journal of Clinical Oncology (2012)

3026 Background: Debio 0932 is an oral second-generation heat shock protein 90 (HSP90) inhibitor that has shown extended tumor retention, blood-brain-barrier penetration, and promising anti-tumor activity both as monotherapy and combination against a broad range of tumors in pre-clinical models. Here we report the results of the dose escalation part of a phase I study in patients with advanced solid tumors or lymphoma (NCT01168752). Methods: This was an open-label, non-randomized, 3 + 3 dose-escalation study to determine the maximum tolerated dose (MTD) of Debio 0932 when given QD or Q2D during the first 30 days of treatment in patients with advanced solid tumours or lymphoma resistant to standard therapy. The starting dose in both treatment groups was 50mg. Doses were increased according to an algorithm based on observed toxicity and dose limiting toxicities (DLT). Tumor assessments were performed every 8 weeks. Results: Patient characteristics and results are summarized below. DLTs occurred at 1600mg in both dose groups. Adverse events (AE) were mostly CTCAE grade 1 or 2, with no apparent dose relationship. No ocular or cardiac toxicity was observed. The main reason for treatment withdrawal was progressive disease. Investigator-reported cases of SD and PR were observed. Conclusions: Debio 0932 mono-therapy was generally well tolerated and showed promising signs of efficacy in patients with advanced solid tumors. The recommended phase II dose, established at 1000mg QD, will be tested in an additional 30 patients in an ongoing expansion study. A phase I-II study of Debio 0932 in combination with standard of care in the first- and second-line treatment of NSCLC is planned. [Table: see text]
<i>Notes from the Field</i>: Adverse Events Following a Mass Yellow Fever Immunization Campaign — Kongo Central Province, Democratic Republic of the Congo, September 2016
Authors: John O. Otshudiema, Nestor G. Ndakala, Maurice L. Loko, Elande-taty K. Mawanda, Gaston P. Tshapenda, Jacques M. Kimfuta, Abdou S. Gueye, Jacob Dee, Rossanne M. Philen, Coralie Giese, Christopher S. Murrill, Ray R. Arthur, Benoit I. Kebela
Journal: MMWR Morbidity and Mortality Weekly Report (2017)